Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Short-term Investments: 2016-2025

Historic Short-term Investments for Heron Therapeutics (HRTX) over the last 10 years, with Sep 2025 value amounting to $12.4 million.

  • Heron Therapeutics' Short-term Investments fell 72.49% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year decrease of 72.49%. This contributed to the annual value of $33.5 million for FY2024, which is 35.28% down from last year.
  • Per Heron Therapeutics' latest filing, its Short-term Investments stood at $12.4 million for Q3 2025, which was down 48.51% from $24.1 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Short-term Investments ranged from a high of $106.7 million in Q1 2021 and a low of $12.4 million during Q3 2025.
  • In the last 3 years, Heron Therapeutics' Short-term Investments had a median value of $33.5 million in 2024 and averaged $35.8 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first tumbled by 73.47% in 2021, then spiked by 147.50% in 2024.
  • Over the past 5 years, Heron Therapeutics' Short-term Investments (Quarterly) stood at $67.0 million in 2021, then grew by 3.65% to $69.5 million in 2022, then fell by 25.55% to $51.7 million in 2023, then plummeted by 35.28% to $33.5 million in 2024, then slumped by 72.49% to $12.4 million in 2025.
  • Its Short-term Investments stands at $12.4 million for Q3 2025, versus $24.1 million for Q2 2025 and $31.4 million for Q1 2025.